Mai Volker, Ukhanova Maria, Visone Lee, Abuladze Tamar, Sulakvelidze Alexander
Department of Microbiology and Cell Science, University of Florida, Gainesville, FL 32611, USA.
Int J Microbiol. 2010;2010:624234. doi: 10.1155/2010/624234. Epub 2010 Jun 24.
To investigate the efficacy of phage supplementation in reducing pathogen numbers, mice were treated via oral gavage with a Listeria monocytogenes phage preparation (designated ListShield) before being orally infected with L. monocytogenes. The concentrations of L. monocytogenes in the liver, spleen, and intestines were significantly lower (P < .05) in the phage-treated than in the control mice. Phage and antibiotic treatments were similarly effective in reducing the levels of L. monocytogenes in the internal organs of the infected mice. However, the significant weight loss detected in the control and antibiotic-treated groups was not observed in the infected, ListShield-treated mice. Long-term (90 days), biweekly treatment of uninfected mice with ListShield did not elicit detectable changes in the microbiota of their large intestines or deleterious changes in their health. Our data support the potential feasibility of using bacteriophages to control proliferation of L. monocytogenes in mice without affecting commensal microbiota composition.
为了研究补充噬菌体在减少病原体数量方面的效果,在小鼠经口感染单核细胞增生李斯特菌之前,通过口服灌胃给予其单核细胞增生李斯特菌噬菌体制剂(命名为ListShield)进行治疗。与对照小鼠相比,经噬菌体治疗的小鼠肝脏、脾脏和肠道中的单核细胞增生李斯特菌浓度显著更低(P < 0.05)。噬菌体和抗生素治疗在降低感染小鼠内脏器官中单核细胞增生李斯特菌水平方面同样有效。然而,在感染并接受ListShield治疗的小鼠中未观察到在对照组和抗生素治疗组中检测到的显著体重减轻。对未感染小鼠进行为期90天、每两周一次的ListShield治疗,未引起其大肠微生物群的可检测变化或对其健康的有害变化。我们的数据支持使用噬菌体控制小鼠体内单核细胞增生李斯特菌增殖而不影响共生微生物群组成的潜在可行性。